Replies to post #81983 on Biotech Values

[DewDiligence]

VRTX - Study C208 data of telaprevir administered BID or TID will be presented at AASLD

This study will be the strongest test yet of the Telaprevir rash. If the rash proves to be manageable with BID dosing, it ought to be manageable with TID dosing.